Clinical study of Integrum’s OPRA™ Implant System on below-knee amputations will include up to 30 patients and is fully funded by the Department of Defense
Mölndal, Sweden – November 10, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the US Department of Defense has decided to fully fund a clinical study of OPRA™ Implant System on up to 30 patients with transtibial (below-knee) amputations. As previously announced, the study will be performed by the Walter Reed National Military Medical Center in Bethesda, Maryland. Integrum will supply OPRA™ Implant Systems to Walter Reed on commercial terms.The OPRA[TM] Implant System clinical study on the below-knee amputation level recently received FDA approval,